Kestra Medical Technologies (NASDAQ:KMTS) Insider Alfred Ford, Jr. Sells 13,015 Shares of Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Alfred Ford, Jr. sold 13,015 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $23.90, for a total value of $311,058.50. Following the completion of the sale, the insider directly owned 105,839 shares in the company, valued at $2,529,552.10. This represents a 10.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kestra Medical Technologies Price Performance

NASDAQ KMTS traded up $1.16 on Monday, reaching $23.99. The company’s stock had a trading volume of 373,728 shares, compared to its average volume of 404,856. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. The stock has a market cap of $1.41 billion, a PE ratio of -9.91 and a beta of 0.58. The firm’s 50 day moving average is $22.62 and its two-hundred day moving average is $22.48.

Kestra Medical Technologies (NASDAQ:KMTS) last released its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%.The business had revenue of $28.64 million during the quarter. As a group, sell-side analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Analyst Upgrades and Downgrades

KMTS has been the topic of a number of recent research reports. Weiss Ratings cut Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. BTIG Research increased their price target on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a report on Wednesday, July 15th. The Goldman Sachs Group decreased their target price on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Finally, Oppenheimer began coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating on the stock. Three equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Hold” and a consensus target price of $27.83.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Farther Finance Advisors LLC acquired a new position in Kestra Medical Technologies in the 4th quarter worth about $31,000. Russell Investments Group Ltd. grew its stake in shares of Kestra Medical Technologies by 43.5% in the 4th quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after buying an additional 474 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of Kestra Medical Technologies by 148.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,738 shares of the company’s stock valued at $65,000 after buying an additional 1,638 shares in the last quarter. Daiwa Securities Group Inc. acquired a new position in Kestra Medical Technologies in the fourth quarter worth approximately $72,000. Finally, Brown Brothers Harriman & Co. raised its position in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after acquiring an additional 656 shares in the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.